B
BCRX icon

Braidwell’s BioCryst Pharmaceuticals BCRX Stock Holding History

Braidwell’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-3,379,577
Closed -$17.2M – 78
2024
Q1 		$17.2M Sell
3,379,577
-2,338,900
-41% -$13.2M 0.55% 54
2023
Q4 		$34.3M Buy
5,718,477
+355,497
+7% +$2.06M 1.26% 31
2023
Q3 		$38M Buy
5,362,980
+2,571,100
+92% +$18.5M 1.2% 34
2023
Q2 		$19.7M Buy
2,791,880
+846,746
+44% +$6.79M 0.64% 54
2023
Q1 		$16.2M Buy
+1,945,134
New +$18.7M 0.54% 58

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Braidwell's BCRX Position: Q2 2024 in Review

Braidwell sold out of BioCryst Pharmaceuticals (BCRX) in Q2 2024, closing a stake of 3,379,577 shares — an estimated $17.2M sold.

Braidwell first reported a position in BCRX in Q1 2023 and held it in 5 quarters. The position peaked at $38M in Q3 2023. 242 funds tracked by Wall St. Rank hold BCRX as of Q2 2024.

  • Braidwell reported no remaining BioCryst Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Braidwell sold 3,379,577 BioCryst Pharmaceuticals shares in Q2 2024, an estimated $17.2M.
  • Braidwell first reported a position in BioCryst Pharmaceuticals in Q1 2023 and held it in 5 quarters.
  • Braidwell's BioCryst Pharmaceuticals position peaked at $38M in Q3 2023.
  • 242 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2024.

Based on Braidwell's 13F filing for Q2 2024, filed 14 Aug 2024.